Suppr超能文献

发现新型嘌呤衍生物,对 c-Src 酪氨酸激酶具有强效和选择性抑制活性。

Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.

机构信息

Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, PR China.

出版信息

Bioorg Med Chem. 2010 Jul 1;18(13):4615-24. doi: 10.1016/j.bmc.2010.05.032. Epub 2010 May 19.

Abstract

We report here the discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase by adopting a strategy integrating focused combinatorial library design, virtual screening, chemical synthesis, and bioassay. Thirty two compounds were selected and synthesized. All compounds showed potent inhibitory activity against c-Src kinase with IC₅₀ values ranging from 3.14 μM to 0.02 μM. Compound 5i was identified as one of the most potent agent with an IC₅₀ 120 times lower than those of the hits. The high hit rate (100%) and the potency of the new Src kinase inhibitors demonstrated the efficiency of the strategy for the focused library design and virtual screening. The novel active chemical entities reported here should be good leads for further development of purine-based anticancer drugs targeting Src tyrosine kinase.

摘要

我们在此报告了一种通过整合靶向组合文库设计、虚拟筛选、化学合成和生物测定的策略,发现了具有强效和选择性抑制活性的新型嘌呤衍生物对 c-Src 酪氨酸激酶。我们选择并合成了 32 种化合物。所有化合物对 c-Src 激酶均显示出很强的抑制活性,IC₅₀ 值范围为 3.14 μM 至 0.02 μM。化合物 5i 被鉴定为最有效的抑制剂之一,其 IC₅₀ 值比阳性对照低 120 倍。新 Src 激酶抑制剂的高命中率(100%)和效力证明了该策略对于靶向文库设计和虚拟筛选的有效性。这里报道的新型活性化学实体应该是进一步开发基于嘌呤的针对 Src 酪氨酸激酶的抗癌药物的良好先导化合物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验